Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus

• Main Authors: Gagik R. Galstyan, Elena G. Starostina, Nikolay N. Yakhno, Irina V. Gurieva, Maxim V. Churyukanov, Igor A. Strokov, Alla Y. Tokmakova, Mikhail L. Kukushkin, Anatoly I. Martynov, Marina V. Shestakova
• Format: Article
• Language: English
• Published: Endocrinology Research Centre 2019-10-01
• Series: Сахарный диабет
• Subjects: diabetes mellitus; diabetic peripheral neuropathy; painful neuropathy; neuropathic pain; diagnosis; treatment
• Online Access: https://dia-endojournals.ru/dia/article/viewFile/9625/7320

Diabetic peripheral neuropathy is a common chronic complication of diabetes mellitus, significantly impairing well-being, quality of life and functioning of patients. The prevalence of diabetic peripheral neuropathy in the Russian Federation ranges from 0.1% to 67.2% in type 1 and from 0.1 to 42.4% in type 2 diabetes mellitus. However, based on the large-scale epidemiological studies, the true prevalence of diabetic peripheral neuropathy is much higher (50 to 70%), with its painful variant occurring in 16% to 30% of patients. Despite the fact that diabetic peripheral neuropathy remains the most common chronic complication of diabetes mellitus, its diagnosis and therapy leave much to be desired. To optimize diagnostic and treatment approaches to painful diabetic peripheral neuropathy, a group of experts representing the leading Russian professional medical associations has developed clinical guidelines for the diagnosis and rational therapy of patients with painful diabetic peripheral neuropathy. This document presents practical aspects of the clinical diagnosis of painful diabetic peripheral neuropathy and an algorithm for differential diagnosis of pain in the lower extremities in patients with diabetes mellitus. The use of symptomatic analgesics with central action, such as anticonvulsants, antidepressants and opioids, is based on the main aspects of neuropathic pain pathophysiology. The characteristics of each drug class are given, with consideration of evidence on their efficacy, tolerability, and the possibility of combination therapy. The data on the first, second, and third lines of agents is presented in accordance with several international clinical guidelines. The need for a tailored drug choice, taking into account the evidence-based data on their efficacy and safety, concomitant drug therapy, tolerability, cost and preferences of the patient, age of the patient and concomitant disorders, is emphasized.